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Abstract
Previously, the spin trapping agent phenyl-N-tert-butylnitrone (PBN) has been shown to decrease the level of nitric oxide
synthase mRNA in vivo. This inhibition is suggested to be an underlying mechanism for PBN’s wide variety of
pharmacological actions in animal models. However, the determination of PBN’s cellular pharmacological activities has not
been carried out, but is necessary for the understanding of the effects in vivo. Since the known pharmacological effects of
PBN are primarily anti-inflammatory in nature, in this study we determined the inhibitory activities of PBN against two
inflammatory factors: inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX2). We show here that PBN
decreases steady state COX2 mRNA level and COX2 catalytic activity in macrophage cell culture at supra-pharmacological
concentrations. While PBN decreases iNOS mRNA, it does not inhibit iNOS catalytic activity, which is consistent with
previous in vivo studies. We also studied nuclear factor UB (NF-UB), a transcription factor that can rapidly activate the
expression of genes involved in inflammatory, immune and acute phase responses. The binding of NF-UB to iNOS gene has
been shown to be critical for iNOS gene expression, and the promoter region of COX2 gene contains NF-UB consensus
sequence. We show that PBN inhibits lipopolysaccharide-mediated increase of NF-UB DNA binding activity with a lower
concentration than that for the non-steroidal anti-inflammatory drug (NSAID), salicylate. Furthermore, we show that PBN
inhibits COX2 catalytic activity, suggesting that PBN has an NSAID-like function. ß 1998 Elsevier Science B.V. All rights
reserved.
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1. Introduction
The spin trapping agent phenyl-N-tert-butylni-
trone (PBN) has been shown to prevent death after
endotoxin shock in rodents when administered with a
lethal dose of endotoxin [1^5]. In the same event,
PBN has been shown to signi¢cantly reduce the for-
mation of nitric oxide in the liver [6,7]. This reduc-
tion has been shown to be associated with the de-
crease of steady-state nitric oxide synthase (iNOS)
mRNA level [7]. In animal models, other pharmaco-
logical activities of PBN include neuro-protection
[8^11], anti-aging [12^14], and anti-diabetic e¡ect
[15], suggesting that the e¡ect of PBN is largely
anti-in£ammatory. Although these pharmacological
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e¡ects are diverse, PBN’s inhibition against iNOS
mRNA synthesis is suggested to be the common
underlying mechanism. But the relationship between
PBN’s inhibition of iNOS mRNA and its free radical
trapping capabilities is not understood.
Macrophages are considered to play a major role
in endotoxin shock [16]. When activated by endotox-
in, macrophages elicit the formation of in£ammatory
cytokines, which then activate macrophages and oth-
er cells to promote iNOS gene induction. Although
nitric oxide is necessary for physiological activities,
the highly expressed iNOS produces large amounts
of nitric oxide in cells and tissues in an uncontrolled
manner, resulting in a catastrophic breakdown of
various physiological functions. PBN’s interaction
with macrophages appears important in this event,
but the speci¢c pharmacological activity of PBN in
isolated cells is not well characterized. In contrast,
cellular anti-in£ammatory functions of other antiox-
idants such as salicylate, N-acetyl cysteine and
L-lipoic acid have been extensively investigated
[17^23]. Salicylate [17^19], N-acetyl cysteine [20,21]
and L-lipoic acid [22] inhibited nuclear factor UB
(NF-UB) and iNOS mRNA in cells but with rela-
tively high concentrations as compared to therapeu-
tic doses. However, it is clear that the determination
of cellular pharmacological activities of these drugs
is necessary for the understanding of pharmacologi-
cal activities in vivo. In the present study, using
isolated macrophages, we determined the inhibitory
activities of PBN against the two major in£amma-
tory enzymes iNOS and inducible cyclooxygenase
(COX2) by quantifying produced nitrite and prosta-
glandin E2 (PGE2), respectively. PBN was also tested
for the alteration of iNOS mRNA and COX2
mRNA levels, and the catalytic activities of these
two enzymes.
A major transcription factor for the iNOS
gene is NF-UB [24], a redox-sensitive transcription
factor that is activated by oxidants and inhibit-
ed by antioxidants [23]. We hypothesized that PBN
may exert an antioxidant e¡ect which prevents
NF-UB from binding to DNA, thus decreasing
iNOS mRNA level. In order to verify this hypothe-
sis, we tested PBN for inhibition of lipopolysacchar-
ide-mediated NF-UB binding activity in macro-
phages.
2. Materials and methods
2.1. Materials
PBN was synthesized in these laboratories and pu-
ri¢ed with vacuum sublimation. PBN was also ob-
tained from commercial sources such as Aldrich
Chemical Co. (Milwaukee, WI). Reagents for nitrite
assay (Griess reaction) were obtained from Fisher
Scienti¢c (Pittsburgh, PA). LPS (from Escherichia
coli) and fetal calf serum (FCS) were purchased
from Sigma Chemical Co. (St. Louis, MO) and
used as received. Sources of other reagents are shown
where the name of the reagent ¢rst appears.
2.2. Macrophage isolation and activation
Primary peritoneal macrophages [25] were ob-
tained from male Balb/c mice (6^8 weeks old, from
Charles-River, Indianapolis, IN), 5 days after intra-
peritoneal injection of eliciting reagent, 4% brewer’s
thioglycollate medium (1.5 ml, Defco, Detroit, MI).
After euthanasia, the peritoneal cavity was infused
with 5 ml ice-cold RPMI 1640 medium (with gluta-
mine, Fisher), which was subsequently collected. The
obtained cell suspension was washed with RPMI
1640 medium twice. Cells were re-suspended in con-
ditioned RPMI 1640 medium containing 5% FCS,
100 Wg/ml streptomycin (Sigma), and 100 units/ml
penicillin (Sigma), and seeded onto 24-well cell cul-
ture plates (Fisher). Cells were incubated for 2 h at
37‡C in a 5% CO2 incubator to promote adherence
to the bottom of the well. These cells were then in-
cubated in conditioned RPMI 1640 medium contain-
ing LPS (50 ng/ml, from E. coli, serotype 0127:B8,
Sigma) and interferon Q (IFN-Q, 250 U/ml) in the
absence or presence of PBN (1 to 10 mM). Incu-
bation lasted 5 h for Northern analysis and 15 h
for immunoblotting, and 1 h for NF-UB determina-
tion.
Cell viability after incubation with 1, 5, and 10 mM
PBN for 15 h in conditioned RPMI 1640 medium
was determined using LDH release assay (Sigma).
LIVE/DEAD viability/cytotoxicity kit (Molecular
Probes, Eugene, OR) was also used to access the
cytotoxicity of PBN. The LIVE (viability) method
is based on the measurement of intracellular esterase
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activity through calcein AM £uorescence and the
DEAD (cytotoxicity) method measures plasma
membrane integrity through £uorescence from ethi-
dium homeodimer. These assays were performed
three times using cells obtained from separate ani-
mals.
2.3. Determination of nitrite formation
Nitrite, the oxidation product of NO, was meas-
ured by the Griess reaction [26]. Cells were activated
with LPS (50 ng/ml) and IFN-Q (250 U/ml) in the
absence or presence of PBN. After incubation for
15 h, supernatants were discarded and replaced
with the fresh conditioned RPMI 1640 medium fol-
lowed by 3 h incubation. iNOS expression was meas-
ured by means of the nitrite amount in the medium.
The medium from incubated cells was mixed with an
equal volume of the Griess reagent (Fisher) in a well
of a 96-well cell culture plate. The absorption at 540
nm was recorded with a micro-plate reader (Thermo-
max, Molecular Device, Palo Alto, CA), and the
absorption coe⁄cient was calibrated using a sodium
nitrite solution standard (Fisher).
For the iNOS catalytic activity measurement, cells
were incubated for 15 h with LPS (50 ng/ml) and
IFN-Q (250 U/ml) to fully express iNOS. Supernatant
was discarded and fresh medium containing PBN
was added, followed by 3 h incubation. Nitrite in
this medium was quanti¢ed with the Griess reaction.
Each experiment was performed in triplicate and re-
peated three times using cells obtained from separate
animals.
2.4. Determination of PGE2 production
PGE2 produced from activated macrophages was
quanti¢ed using an enzyme immunoassay (EIA) kit
for PGE2 (Cayman Chemical, Ann Arbor, MI). Cells
were activated by LPS (50 ng/ml) and IFN-Q (250 U/
ml) to express COX2 in the presence or absence of
PBN. Cells were washed twice, and the substrate
(30 WM sodium arachidonate, Sigma) was added in
conditioned RPMI 1640 medium. After 0.5 h incu-
bation, the produced PGE2 in the medium was quan-
ti¢ed to determine COX2 expression. These media
were diluted and transferred to a PGE2 antibody-
coated 96-well culture plate in the EIA kit and
treated according to manufacturer’s instruction.
Absorbance at 410 nm was recorded using a micro-
plate reader.
For the COX2 catalytic activity measurement,
COX2 in cells was fully expressed by the incubation
with LPS (50 ng/ml) and IFN-Q (250 U/ml) for 15 h.
Subsequently, cells were washed and added with
arachidonate (30 WM), followed by 0.5 h incubation
in the presence of PBN. The produced PGE2 in the
medium was quanti¢ed to determine COX2 catalytic
activity. Each experiment was performed in triplicate
and repeated three times using cells obtained from
separate animals.
2.5. Northern blotting
mRNA for iNOS and COX2 in macrophages was
determined by Northern blotting. Mouse peritoneal
macrophages were incubated with LPS (50 ng/ml)
and IFN-Q (250 U/ml) with or without PBN for 5 h.
At this incubation time it was con¢rmed that the
expression of the mRNA was maximized (data not
shown). Total RNA was isolated from macrophages
(3 million cells) using TRIzol (Life Technologies,
Gaithersburg, MD) according to manufacturer’s in-
structions. Equivalent amounts of total RNA (typi-
cally 20 Wg) were loaded onto a 1% formaldehyde^
agarose (Fisher) gel. After electrophoresis, RNA was
transferred overnight to a nylon membrane (MSI,
Westboro, MA) by capillary action and secured to
the membrane by UV cross-linking. After soaking
the membrane in the hybridization bu¡er at 65‡C
for 30 min, hybridization (65‡C) was performed
overnight with 32P-labeled cDNA for mouse iNOS
(ALEXIS, San Diego, CA) or 32P-labeled oligonu-
cleotide probe for COX2 (Molecular Biology Re-
source Facility, University of Oklahoma Health Sci-
ence Center, Oklahoma City, OK). 32P-Labeled
probe for the ribosomal RNA 28s (Santa Cruz Bio-
technology) was used to con¢rm equal loading of
mRNA. The blot was then washed twice and ex-
posed to X-ray ¢lm (Fuji) at 380‡C for 15 h. Den-
sities of the blots were determined using Eagle Eye II
still video system (Stratagene, La Jolla, CA). North-
ern blotting experiments were conducted three times
using cells obtained from separate animals.
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2.6. Immunoblotting
Relative amounts of iNOS and COX2 protein ex-
pressed in macrophages were quanti¢ed using immu-
noblotting. Cells were incubated for 15 h with LPS
(50 ng/ml), IFN-Q (250 U/ml), and with or without
PBN at 37‡C. The protein expression in cells leveled
in 15 h incubation (data not shown). Subsequently,
the boiling cell-lysis bu¡er (250 mM Tris^HCl (pH
6.8), 4% SDS, 10% glycerol, 0.006% bromophenol
blue, and 2% L-mercaptoethanol) was added to the
well and cells were disrupted in the medium. The
lysate was centrifuged at 14 000Ug for 30 min and
the supernatant was subjected to electrophoresis. To-
tal protein in the supernatant was determined using
Lowry’s method (Total protein assay kit, Sigma) and
the same amount of protein was loaded to each lane
of the gel. Electrophoresis was performed on an
SDS^PAGE (7.5^12% gradient). Separated protein
bands were transferred and treated with rabbit
anti-mouse macrophage iNOS or COX2 antibody
(0.1 Wg/ml, Transduction Lab), and then treated
with horseradish peroxidase-conjugated IgG anti-
body (Amersham). The bands were detected by the
ECL system (Amersham) with a typical exposure
time of 15 s. Densities of immunoblots were quanti-
¢ed using the same system as used in Northern blot-
ting. Immunoblotting was performed three times us-
ing cells obtained from separate animals.
2.7. Electrophoretic mobility shift assay (EMSA)
The binding activity of NF-UB in nuclear extracts
of LPS/IFN-Q-stimulated macrophages to its consen-
sus oligonucleotide was evaluated by means of
EMSA, using a non-radioactive EMSA kit, DIG
Gel Shift Kit available from Boehringer-Mannheim
(Indianapolis, IN). Brie£y, cells were incubated with
LPS (50 ng/ml), IFN-Q (250 U/ml), and with or with-
out PBN for 1 h. Nuclear extracts were prepared as
described by Dignam et al. [27]. The NF-UB consen-
sus oligonucleotide (5P-AGT TGA GGG GAC TTT
CCC AGG C3P, Santa Cruz Biotechnology, Santa
Cruz, CA) was end-labeled with digoxigenin (DIG)
using terminal transferase. Nuclear extracts (10 Wg)
were added to DIG-labeled NF-UB oligonucleotide
(0.8 ng) in a bu¡er containing 2 Wg of poly(dI-dC),
10 mM Tris^HCl (pH 7.5), 50 mM NaCl, 1 mM
dithiothreitol, 1 mM EDTA, and 5% glycerol (total
volume of 20 Wl). This solution was subjected to elec-
trophoresis on 5% non-denaturing polyacrylamide
gel, followed by electro-transfer to nylon membrane.
The non-labeled NF-UB-speci¢c oligonucleotide was
used as a competitive probe to con¢rm the speci¢c
binding. Furthermore, a mutant probe (Santa Cruz
Biotechnology) was used to demonstrate protein
binding speci¢city. The membrane was subsequent-
ly treated with anti-DIG-antibody, which then
treated with alkali phosphatase-conjugated IgG.
The chemiluminescent substrate CSPD (Boehringer-
Mannheim) was added and the resulting chemilumi-
nescence was detected by autoradiography. The
band densities were quanti¢ed using the same
system as used in Northern blotting. EMSA was
performed twice using cells obtained from separate
animals.
Fig. 1. Inhibition of iNOS and COX2 catalytic activity by PBN
as determined by nitrite and PGE2 production. Nitrite (broken
line) and PGE2 (solid line) were quanti¢ed as a measure of cat-
alytic activity of iNOS and COX2, respectively. Mouse perito-
neal macrophages were incubated with LPS (50 ng/ml) plus
IFN-Q (250 U/ml) for 15 h to fully express iNOS and COX2.
For nitrite assay, fresh medium with or without PBN was
added and incubated for 3 h. Griess reagent was added to
supernatant to quantify nitrite spectrophotometrically. In PGE2
determination, the activated cells were incubated with the me-
dium containing sodium arachidonate (30 WM) with or without
PBN. Amounts of PGE2 in supernatant were quanti¢ed with
enzyme immunoassay. Points in the ¢gure show the percent
amount relative to the amount obtained in PBN-free system.
Error bars denote S.D. calculated from the data obtained from
triplicate measurement from three separate animals (average of
total of nine data points).
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3. Results
3.1. PBN’s e¡ect on cell viability
Cell viability after incubation with PBN for 15 h
was measured with LDH release assay (n = 3).
The results were 96 þ 6% (PBN 1 mM), 92 þ 7%
(PBN 5 mM), and 81 þ 10% (PBN 10 mM). The re-
sults from LIVE/DEAD assay were 96 þ 2% live/
2 þ 1% dead (PBN 1 mM), 94 þ 2% live/8 þ 5% dead
(PBN 5 mM), and 82 þ 3% live/11 þ 4% dead (PBN
10 mM).
3.2. PBN’s e¡ect on iNOS and COX2 catalytic
activities
Experiments were conducted to determine whether
PBN inhibits iNOS and COX2 catalytic activity.
Macrophages which had been incubated with LPS
plus IFN-Q for 15 h were used as the source of
iNOS and COX2. The amounts of nitrite and
PGE2 produced from macrophages in the presence
of PBN were plotted in Fig. 1. This shows that
PBN is an inhibitor of COX2 catalytic activity with
IC50 (concentration at 50% inhibition) approximately
8 mM. PBN is not an inhibitor of iNOS catalytic
activity.
3.3. Inhibition of iNOS and COX2 protein expression
Expression of iNOS and COX2 protein was eval-
uated in macrophages which had been activated
with LPS and IFN-Q in the presence of PBN for
15 h. Immunoblotting of iNOS and COX2 protein
indicated that PBN reduces these proteins in a dose-
dependent manner (Fig. 2, top panel). These results
are consistent with those obtained by nitrite assay.
3.4. Inhibition of iNOS mRNA and COX2 mRNA
The expression of iNOS and COX2 mRNA was
determined to show that PBN alters steady-state con-
centrations of iNOS and COX2 mRNA. Northern
blot analysis of macrophages treated with PBN
showed suppression of both iNOS mRNA and
COX2 mRNA (Fig. 2, bottom panel) in a dose-de-
pendent manner. The densities of those bands were
normalized with respect to corresponding 28S bands,
Fig. 2. Inhibition of iNOS and COX2 by PBN as determined with immunoblotting and Northern blotting. Mouse peritoneal macro-
phages were activated with LPS and IFN-Q for 15 h in the presence of the indicated concentrations of PBN. Whole cell protein was
subjected to SDS^PAGE analysis. Bands for iNOS (131 kDa) and COX2 (70 kDa) were detected using monoclonal antibody for
iNOS and COX2 (top panel). For Northern blotting, cells were activated with LPS and IFN-Q for 5 h in the presence of the indicated
concentrations of PBN. Whole cell RNA was subjected to electrophoretic analysis with agarose gel. The separated bands were hybrid-
ized with the radiolabeled iNOS or COX2 probe and detected (bottom panel). Fluorograms indicated as 28S are from 28S ribosomal
RNA, whose densities indicate the loaded amount of RNA to the gel. Densities of these bands were determined to estimate percent
inhibition.
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and are plotted in Fig. 4. This graph assumes the
density in the absence of PBN as 100%.
3.5. E¡ect of PBN on NF-UB binding
DNA binding activity of NF-UB in nuclear ex-
tracts in LPS/IFN-Q-stimulated macrophages was
evaluated by means of EMSA. The amount of NF-
UB that bound to the NF-UB-speci¢c oligonucleotide
increased in stimulated cells (Fig. 3, lanes 2 and 6) as
compared to unstimulated cells (Fig. 3, lane 1). The
band disappeared in the presence of excess non-la-
beled (cold competitive) NF-UB-speci¢c oligonucleo-
tide (Fig. 3, lane 7). Furthermore, the NF-UB band
from the sample added with a mutant probe showed
minor change (Fig. 3, lane 8). These two facts sup-
port the authenticity of the NF-UB band. Nuclear
extracts obtained from PBN-treated cells exhibited
a reduced amount of NF-UB-oligonucleotide com-
plex (Fig. 3, lanes 3^5), indicating that PBN inhib-
ited NF-UB in a concentration-dependent manner.
The decrease of the band density strongly suggests
that the amount of NF-UB that has DNA binding
activity was decreased by the presence of PBN. IC50
of PBN for NF-UB inhibition was estimated to be
approximately 8 mM. Relative densities of NF-UB
bands were plotted in Fig. 4.
4. Discussion
In these experiments, we investigated the cellular
pharmacological activities of PBN using mouse peri-
toneal macrophages in order to obtain a basic
knowledge to understand PBN’s in vivo activities.
The cytotoxicity of PBN was low even at 10 mM,
suggesting that the present inhibition activities were
not caused by the toxicity of PBN. In macrophages,
iNOS mRNA was decreased in the presence of PBN
to one-half at approximately 6 mM. Although PBN
inhibited iNOS mRNA in vivo; however, in mice,
PBN’s ID50 for iNOS mRNA in the liver was ap-
proximately 1 mmol/kg [7]. If one assumes that ani-
mal body is simulated by a water bag, this number
may be translated into 1 mM PBN which is homo-
geneously distributed in the body. It is not surprising
Fig. 4. Inhibition of NF-UB, iNOS mRNA, and COX2 mRNA
by PBN as illustrated by the reduction of the blot density. NF-
UB in the macrophage nucleus was quanti¢ed by £uorescence-
detected EMSA as described in Section 2, and the percent den-
sity of NF-UB band as compared to the control (no PBN) band
was plotted as a function of PBN concentration (solid line).
mRNAs of iNOS and COX2 were quanti¢ed by Northern blot-
ting as described in Fig. 2. The relative band density was quan-
ti¢ed and plotted as a function of PBN concentration (dotted
line and dashed line).
Fig. 3. Inhibition of NF-UB by PBN as determined by £uores-
cence-detected electrophoretic mobility shift assay (EMSA).
Mouse peritoneal macrophages were stimulated with LPS and
IFN-Q for 1 h in the presence of indicated concentrations of
PBN. Nuclear extracts from these cells were obtained and com-
bined with a labeled NF-UB-probe nucleotide. NF-UB was
quanti¢ed from the density of the retarded bands (double bands
marked as NF-UB) on the gel. Lane 1, (3) non-stimulated;
lane 2, (+) stimulated; lane 3, stimulated in the presence of
10 mM PBN; lane 4, stimulated in the presence of 5 mM
PBN; lane 5, (3) stimulated in the presence of 1 mM PBN;
lane 6, (+) stimulated; lane 7, cold ^ an excess amount of non-
labeled NF-UB probe added (competition assay); lane 8, mutant
^ an excess amount of mutant NF-UB probe added (speci¢city
assay).
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to see such large discrepancies in doses between in
vivo and cellular systems [17^19]. Although the
reason for such discrepancies is not well understood,
in the case of PBN, preferential distribution of the
drug to the lipid-rich organ, such as the liver, may
partly account for this discrepancy. PBN is a lipo-
philic agent with octanol/water partition ratio of
15:1 [28].
PBN inhibited both COX2 mRNA expression and
COX2 catalytic activity. This means PBN can reduce
PGE2 in two ways: by decreasing COX2 expression
and inhibiting COX2 activity, suggesting that PBN
could be classi¢ed as an NSAID (non-steroidal anti-
in£ammatory drug), because NSAIDs’ major phar-
macological action is by the COX inhibition [29].
Also, PBN decreased the formation of nitrite and
PGE2 (Fig. 1) due to the decrease of iNOS/COX2
protein, which is shown by Western blotting results.
This decrease in proteins must be the result from the
decrease in iNOS/COX2 mRNA. These results indi-
cate that PBN inhibits iNOS and COX2 at the tran-
scription or pre-transcription stage. In addition, evi-
dence is increasing that many in£ammatory events
are associated with co-existence of active iNOS and
COX2 [30^33]. NO and PGE2 appear to enhance the
in£ammatory action of each other. Indeed, co-inhi-
bition of iNOS and COX2 by two independent in-
hibitors has been shown to be very e¡ective in the
carageenan-induced edema model in rats [32]. It is
possible that PBN’s pharmacological action is en-
hanced by the co-reduction of NO and PGE2. How-
ever, the role of COX2 inhibition in PBN’s pharma-
cological action in vivo remains to be elucidated.
There is a clear inhibition of NF-UB by PBN in
LPS/IFN-Q-activated cells (Fig. 3). IC50 for the NF-
UB inhibition was estimated to be approximately
8 mM and is consistent with that of iNOS mRNA
inhibition, suggesting that NF-UB plays a major role
in the transcription of the iNOS gene [24]. It has
been shown that the promoter (5P-£anking) region
of COX2 gene also contains two separate NF-UB
consensus sequences [34]. Similar IC50s for COX2
mRNA (10 mM) and NF-UB (8 mM) suggest the
importance of NF-UB in COX2 gene transcription
[35]. It should be noted that sodium salicylate and
aspirin have shown to inhibit NF-UB in cells at rel-
atively higher concentrations such as IC50 = 15 mM
[17].
NF-UB is a redox-sensitive transcription factor and
has been shown to be activated by pro-oxidants such
as hydrogen peroxide, and NF-UB is also inhibited
by many antioxidants [23,36^38]. In resting cells,
NF-UB exists in the cytosol as a complex with the
endogenous inhibitor IUB. It was proposed that oxy-
gen radicals directly destroy IUB, activating NF-UB
and promoting its translocation to the nucleus and
the subsequent trans-activation. The question to be
asked is whether PBN acts like a radical scavenger
which directly protects IUB from destruction. Such
simple scenarios do not seem to hold because of
the recent ¢nding of IUB kinase (IKK) [39^42]. IUB
destruction is shown to be preceded by its phospho-
rylation by IKK, followed by ubiquitination and
proteolysis. Moreover, other kinases have also been
shown to respond to oxidative stress to elevate their
activities, which could contribute to the destruction
pathway. It is possible that antioxidants like PBN act
as radical scavengers to keep these kinases from ac-
tivation.
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